Key clinical point: Mutation in isocitrate dehydrogenase 2 ( IDH2) gene predicted a favorable response to daunorubicin, cytarabine, and cladribine (DAC) regimen in patients with normal karyotype acute myeloid leukemia (NK-AML).
Major finding: IDH2 mutation had a positive impact on overall survival in patients treated with DAC regimen (54% vs. 33%; P = .0087) but not in those treated with daunorubicin+cytarabine (DA; 21% vs. 23%; P = .22) regimen. Moreover, DAC induction was independently associated with a reduced risk for death when the observations were censored at allogeneic hematopoietic stem cell transplant (hazard ratio, 0.21; P = .02).
Study details: Findings are from a retrospective analysis of 398 patients with NK-AML ( IDH2+, n=50) treated with DA (48%), DAC (44%), or DA+fludarabine (8%) regimens.
Disclosures: This study was supported by grants from the Polish Ministry of Science and Education, Polish National Center for Research and Development, and Nicolaus Copernicus University in Bydgoszcz. The authors declared no conflicts of interest.
Source: Libura M et al. Sci Rep. 2021 May 11. doi: 10.1038/s41598-021-88120-y .